<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>a2a - Le Fonti New Pharma Italy</title>
	<atom:link href="https://www.newpharmaitaly.it/tag/a2a/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.newpharmaitaly.it/tag/a2a/</link>
	<description>Il portale delle news in ambito farmaceutico</description>
	<lastBuildDate>Fri, 24 Jul 2020 04:31:14 +0000</lastBuildDate>
	<language>it-IT</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://www.newpharmaitaly.it/wp-content/uploads/2022/12/cropped-favicon-new-pharma-italy-32x32.jpg</url>
	<title>a2a - Le Fonti New Pharma Italy</title>
	<link>https://www.newpharmaitaly.it/tag/a2a/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>SKEMA strengthens its position in China by creating a joint school with Nanjing University and a master&#8217;s degree in entrepreneurship and innovation with Xian&#8217;Jiaotong University </title>
		<link>https://www.newpharmaitaly.it/skema-strengthens-its-position-in-china-by-creating-a-joint-school-with-nanjing-university-and-a-masters-degree-in-entrepreneurship-and-innovation-with-xianjiaotong-university/</link>
					<comments>https://www.newpharmaitaly.it/skema-strengthens-its-position-in-china-by-creating-a-joint-school-with-nanjing-university-and-a-masters-degree-in-entrepreneurship-and-innovation-with-xianjiaotong-university/#respond</comments>
		
		<dc:creator><![CDATA[Elvis Kondi]]></dc:creator>
		<pubDate>Fri, 24 Jul 2020 04:31:14 +0000</pubDate>
				<category><![CDATA[Immedia press]]></category>
		<category><![CDATA[a2a]]></category>
		<category><![CDATA[AEB]]></category>
		<category><![CDATA[integrazione industriale]]></category>
		<guid isPermaLink="false">https://www.adnkronos.com/immediapress/ict/2020/07/24/skema-strengthens-university-position-china-creating-joint-school-with-nanjing-university-and-master-degree-entrepreneurship-and-innovation-with-xian-jiaotong_SjILJZdUabJoMJBcpjb13J.html</guid>

					<description><![CDATA[<p>PARIS, July 24, 2020 /PRNewswire/ -- SKEMA Business School has just signed two new strategic agreements with two excellent Chinese academic institutions: Nanjing Audit University and Xian' Jiaotong University, a member of the prestigious Chinese Ivy League, which brings together the...</p>
<p>L'articolo <a href="https://www.newpharmaitaly.it/skema-strengthens-its-position-in-china-by-creating-a-joint-school-with-nanjing-university-and-a-masters-degree-in-entrepreneurship-and-innovation-with-xianjiaotong-university/">SKEMA strengthens its position in China by creating a joint school with Nanjing University and a master&#8217;s degree in entrepreneurship and innovation with Xian&#8217;Jiaotong University </a> proviene da <a href="https://www.newpharmaitaly.it">Le Fonti New Pharma Italy</a>.</p>
]]></description>
		
					<wfw:commentRss>https://www.newpharmaitaly.it/skema-strengthens-its-position-in-china-by-creating-a-joint-school-with-nanjing-university-and-a-masters-degree-in-entrepreneurship-and-innovation-with-xianjiaotong-university/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Human Horizons and Microsoft partner to create onboard AI assistant for HiPhi </title>
		<link>https://www.newpharmaitaly.it/human-horizons-and-microsoft-partner-to-create-onboard-ai-assistant-for-hiphi/</link>
					<comments>https://www.newpharmaitaly.it/human-horizons-and-microsoft-partner-to-create-onboard-ai-assistant-for-hiphi/#respond</comments>
		
		<dc:creator><![CDATA[Elvis Kondi]]></dc:creator>
		<pubDate>Mon, 13 Jul 2020 07:02:50 +0000</pubDate>
				<category><![CDATA[Immedia press]]></category>
		<category><![CDATA[a2a]]></category>
		<category><![CDATA[acquisizione]]></category>
		<category><![CDATA[Agripower]]></category>
		<category><![CDATA[GOP]]></category>
		<category><![CDATA[PwC TLS]]></category>
		<guid isPermaLink="false">https://www.adnkronos.com/immediapress/auto-e-motori/2020/07/13/human-horizons-and-microsoft-partner-create-onboard-assistant-for-hiphi_dsQ5s9BDPcU1zCxaQ103pM.html</guid>

					<description><![CDATA[<p>SHANGHAI, July 13, 2020 /PRNewswire/ -- At the World Artificial Intelligence Conference 2020 (WAIC 2020) held online this year, Human Horizons announces its strategic partnership with Microsoft to jointly develop an on-board AI assistant, the HiPhiGo, for HiPhi vehicles. Human Horizons is...</p>
<p>L'articolo <a href="https://www.newpharmaitaly.it/human-horizons-and-microsoft-partner-to-create-onboard-ai-assistant-for-hiphi/">Human Horizons and Microsoft partner to create onboard AI assistant for HiPhi </a> proviene da <a href="https://www.newpharmaitaly.it">Le Fonti New Pharma Italy</a>.</p>
]]></description>
		
					<wfw:commentRss>https://www.newpharmaitaly.it/human-horizons-and-microsoft-partner-to-create-onboard-ai-assistant-for-hiphi/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Servier Completes the Acquisition of Symphogen </title>
		<link>https://www.newpharmaitaly.it/servier-completes-the-acquisition-of-symphogen/</link>
					<comments>https://www.newpharmaitaly.it/servier-completes-the-acquisition-of-symphogen/#respond</comments>
		
		<dc:creator><![CDATA[Elvis Kondi]]></dc:creator>
		<pubDate>Thu, 04 Jun 2020 11:31:07 +0000</pubDate>
				<category><![CDATA[Immedia press]]></category>
		<category><![CDATA[a2a]]></category>
		<category><![CDATA[ambiente energia brianza]]></category>
		<category><![CDATA[GOP]]></category>
		<category><![CDATA[Nctm]]></category>
		<category><![CDATA[partnership]]></category>
		<guid isPermaLink="false">https://www.adnkronos.com/immediapress/chimica-e-farmacia/2020/06/04/servier-completes-the-acquisition-symphogen_SKipgfFLfIXdTrukOc1CyM.html</guid>

					<description><![CDATA[<p> PARIS, June 4, 2020 /PRNewswire/ -- Servier, an independent international pharmaceutical company, today announced that it has completed the acquisition of Symphogen A/S.   Symphogen will now function as Servier's antibody center of excellence across multiple therapeutic areas, including oncology. Symphogen, now...</p>
<p>L'articolo <a href="https://www.newpharmaitaly.it/servier-completes-the-acquisition-of-symphogen/">Servier Completes the Acquisition of Symphogen </a> proviene da <a href="https://www.newpharmaitaly.it">Le Fonti New Pharma Italy</a>.</p>
]]></description>
		
					<wfw:commentRss>https://www.newpharmaitaly.it/servier-completes-the-acquisition-of-symphogen/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
